Patent · US Active

Blood treatment with inactivation of circulating nucleic acids

US11344661B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

Fresenius Medical Care Deutschland GmbH · DE

Inventors

Andreas Laubrock · Usingen, DE
Rainer Fislage · Namborn, DE

Key dates

Filing date	Feb 9, 2017
Grant date	May 31, 2022
Priority date	—
Expiry date	Oct 3, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61M2202/206
WIPO fieldMedical technology
WIPO sectorInstruments

Abstract

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.